The US Food and Drug Administration approved three PARP inhibitors for third- and fourth-line ovarian cancer indications based on the results of single-arm studies showing improvement in objective response rate or progression-free survival. But subsequent randomized trials indicate that they may have a detrimental effect on overall survival, leading the sponsors to withdraw the indications.
The three poly (ADP-ribose) polymerase (PARP) inhibitors are Clovis Oncology, Inc.’s Rubraca (rucaparib), AstraZeneca PLC’s Lynparza (olaparib), and...







